Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab induction in moderate to severe Crohn's disease (M15-991, China cohort)
CTR20190772Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Oct 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20190772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190772.